Business Wire

FireTail Names Timo Rüppell as Vice President of Product

24.1.2023 16:30:00 EET | Business Wire | Press release

Share

FireTail Inc., a disruptor in API security, today announced the appointment of Timo Rüppell to the executive leadership team as Vice President of Product. In conjunction with bringing Rüppell on board, FireTail also opened a new company office in Helsinki, Finland. Historically a strong cybersecurity research center, FireTail looks to expand the company’s talent pool based out of Helsinki and the Baltic States.

Rüppell brings to FireTail a wealth of experience in technology development and team leadership for early stage companies. He will work closely with co-founder and CTO Riley Priddle to define and navigate the development of FireTail’s API security platform. Previously, Rüppell served as CTO at Mapita Ltd. where he was focused on product design, including security, privacy, and compliance management. Earlier in his career, Rüppell leveraged his PhD in theoretical particle physics as a researcher for Helsinki Institute of Physics.

“FireTail is thrilled to welcome Timo to our growing team. With his background and expertise, I am confident Timo will make a lasting impact on the direction of FireTail’s products, as well as the API security market,” said Jeremy Snyder, FireTail co-founder and CEO. “It’s an exciting time for our company as we expand our presence globally, and plant roots in new cities. We look forward to all the collaboration and innovation that will take place at our new office in Helsinki.”

“After another year of watching significant breaches and security incidents at major enterprises play out in the news, the need for a new approach to solving the security threats tied to APIs has never been more clear. I look forward to working with the FireTail team to further their mission of offering simple yet effective API security that makes a positive impact and makes the internet a safer place for everyone,” added Rüppell.

FireTail will be at CloudNativeSecurityCon on Feb. 1-2, 2023 in Seattle, Washington. Visit the team in the Startup Zone to learn more about FireTail’s unique approach to solving API security threats.

The company is actively looking for startup-minded individuals with a passion for application security and cloud technologies to join the team. If you are based in Helsinki and are looking for a new opportunity, learn more about FireTail’s open roles and company culture at firetail.io/careers.

About FireTail

FireTail’s API security platform protects programmable interfaces with inline API call inspection and blocking, API security posture management, centralized API audit, and detection and response capabilities. The cloud-based solution helps organizations scale their API landscape and reduce the attack surface. FireTail makes API security as simple as import, setup, done.

FireTail is headquartered in Northern Virginia, with additional offices in Dublin, Ireland and Helsinki, Finland. To learn more about FireTail’s API security solution visit us at https://firetail.io or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tori Odom
LaunchTech Communications
+1-443-752-5466
todom@golaunchtech.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye